Characteristic | Number | % | |
---|---|---|---|
Author numbers | 1 ~ 3 | 21 | 26.25 |
4 ~ 6 | 36 | 45.00 | |
≥ 7 | 23 | 28.75 | |
Published year | 2009 ~ 2015 | 15 | 18.75 |
2016 ~ 2018 | 31 | 38.75 | |
2019 ~ 2021 | 34 | 42.50 | |
Language | English | 46 | 57.50 |
Chinese | 34 | 42.50 | |
Affiliation of the first author | University | 18 | 22.50 |
Hospital | 62 | 77.50 | |
Region of first author | the east region | 51 | 63.75 |
the central region | 11 | 13.75 | |
the west region | 18 | 22.50 | |
Tumor type | Colorectal cancer | 13 | 16.25 |
Non-small cell lung cancer | 37 | 46.25 | |
Hepatocellular carcinoma | 8 | 10.00 | |
Breast cancer | 7 | 8.75 | |
Gastric cancer | 4 | 5.00 | |
Renal cell carcinoma | 2 | 2.50 | |
Myeloid leukemia | 5 | 6.25 | |
Multiple myeloma | 1 | 1.25 | |
Nasopharyngeal carcinoma | 1 | 1.25 | |
Ovarian Cancer | 2 | 2.50 | |
Method of economic evaluation | Cost-utility analysis | 67 | 83.75 |
Cost-effectiveness analysis | 12 | 15.00 | |
Cost minimization analysis | 1 | 1.25 | |
Study designb | Prospective Study | 4 | 5.00 |
Retrospective Study | 10 | 12.50 | |
Modeling Study | 66 | 82.50 | |
Source of funding | No funding | 13 | 16.25 |
Governmenta | 32 | 40.00 | |
Pharmaceutical company | 8 | 10.00 | |
Not mentioned | 27 | 33.75 | |
Study Perspective | Health insurance system | 19 | 23.75 |
Healthcare system | 38 | 47.50 | |
Societal | 10 | 12.50 | |
Patient | 4 | 5.00 | |
Health Care Provider | 1 | 1.25 | |
Not mentioned | 8 | 10.00 | |
Time horizon | Not mentioned | 17 | 21.25 |
< 1 year | 1 | 1.25 | |
1–5 year | 16 | 20.00 | |
6–10 year | 31 | 38.75 | |
> 10 year | 15 | 18.75 | |
Total | 80 | 100.00 |